279 abstracts found.



Real world experience from the use of neoadjuvant FLOT in patients with resectable oesophageal, gastrooesophageal junction (GOJ) and gastric adenocarcinomas. A Yorkshire network audit.

Year:

Session type:

Theme:

Danny Ulahannan1,Konstantinos Kamposioras2,Jeremy Hayden1,Daniel Swinson1,Jonathan Wadsley3,Jessica Tay3,Usman Ahmad4,Simon Brown5,Sohail Mughal5,Jo Dent6,Elizabeth Appleton6,Rajarshi Roy7,Ornella Belvedere8,Kim Last8,Mohan Hingorani1,Matt Seymour1
1Leeds Teaching Hospital,2Christie Hospital,3Weston Park cancer centre, Sheffield,4Mid Yorkshire hospital NHS trust,5Bradford Teaching hospital,6Calderdale and Huddersfield NHS trust,7Hull University teaching hospital,8York teaching hospital

Developing novel platforms for delivery and investigation of vascular-targeted photodynamic therapy (VTP) of pre-clinical models of cancer; towards multi-modality prostate cancer therapy.

Year:

Session type:

Theme:

Richard Bryant1,Hanna Sjoberg1,Yiannis Philippou1,Iain Tullis1,Danny Allen1,Veerle Kersemans1,Emma Murphy1,Sheena Wallington1,Paul Kinchesh1,Stuart Gilchrist1,Gillies McKenna1,Ian Mills1,Tamar Yechezkel2,Dina Preise2,Lilach Agemy2,Sean Smart1,Boris Vojnovic1,Avigdor Scherz2,Freddie Hamdy1,Ruth Muschel1
1University of Oxford,2The Weizmann Institute of Science

18F-FDG-PET in Guided Dose-Painting with Intensity Modulated Radiotherapy in Oropharyngeal Tumours – Final Toxicity and Disease Outcomes of FiGaRO Phase I Multicentre Feasibility Study

Year:

Session type:

Theme:

Delali Adjogatse1,Andriana Michaelidou2,Yae-Eun Suh1,Lucy Pike2,Christopher Thomas3,Owain Woodley4,Beatriz Sanchez Nieto5,Tom Rackley6,Nachi Palaniappan6,Vetrisudar Jayaprakasam7,Mererid Evans6,Mary Lei1,Sally Barrington2,Teresa Guerrero Urbano1
1Dept of Oncology, Guy's and St Thomas NHS Foundation Trust, London, UK,2King's College London and Guy's and St Thomas PET Centre, London, UK, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, UK,3Department of Medical Physics, Guy's and St Thomas NHS Foundation Trust, London, UK, King's College London and Guy's and St Thomas' PET Centre, London, UK, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, UK,4Medical Physics Dept, Velindre University NHS Trust, Cardiff, UK,5Faculty of Physics, Pontificia Universidad Catolica de Chile, Santiago, Chile,6Dept of Oncology, Velindre University NHS Trust, Cardiff, UK,7Wales Research and Diagnostic PET Imaging Centre, Cardiff, UK

Cachexia-related biomarkers predict shortened survival and treatment-related adverse outcomes in a population receiving palliative chemotherapy for lung cancer

Year:

Session type:

Theme:

Joanna Bowden1,Linda Williams2,Amanda Swan3,Richard Skipworth4,Marie Fallon2
1NHS Fife, Kirkcaldy, UK, University of Edinburgh, Edinburgh, UK, University of St Andrews, St Andrews, UK,2University of Edinburgh, Edinburgh, UK,3NHS Fife, Kirkcaldy, UK ,4NHS Lothian, University of Edinburgh, Edinburgh, UK

Chemotherapy-Induced Peripheral Neuropathy: Incidence and Effect on Quality of Life

Year:

Session type:

Theme:

Cheney Wong1
1University of Manchester

The risk of ischemic cerebrovascular disease in head and neck cancer patients after radiotherapy

Year:

Session type:

Theme:

Suzy Kim1,Jin Yong Lee1,Young Ae Kim2,Young Ho Jung3
1SMG-SNU Boramae Medical Center, Seoul,23National Cancer Control Institute, National Cancer Center, Goyang,3Seoul National University Bundang Hospital, Seongnam

RAMPART Renal Adjuvant MultiPle Arm Randomised Trial

Year:

Session type:

Theme:

James Larkin1,Angela Meade2,Tom Powles3,Grant Stewart4,Bhavna Oza2,Laurence Albiges5,Axel Bex6,Hanna Bryant2,Toni Choueiri7,Ian Davis8,Tim Eisen9,Alison Fielding10,Elena Frangou2,Patrick Hanlon10,David Harrison11,Rick Kaplan2,Salena Mulhere10,Paul Nathan12,Brian Rini13,Alastair Ritchie2,Clare Shakeshaft2,Ben Smith2,Martin Stockler14,Max Parmar15
1Royal Marsden Hospital,2MRC CTU at UCL,3St Bartholomew’s Hospital,4University of Cambridge,5Institut Gustave Roussy,6Royal Free Hospital,7Dana-Farber Cancer Institute,8Monash University Eastern Health Clinical School and ANZUP Cancer Trials Group,9AstraZeneca and University of Cambridge,10Patient representative,11University of St Andrews,12Mount Vernon Cancer Centre,13Cleveland Clinic,14University of Sydney,15MCR CTU at UCL

MAESTRO/PERSEUS: A phase II molecular stratification/treatment platform in Metastatic Castration Resistant Prostate Cancer (mCRPC) – PERSEUS1 (pembrolizumab; NCT03506997)

Year:

Session type:

Theme:

Pasquale Rescigno1,Stephanie Burnett1,Nuria Porta1,Ajit Sarvadikar1,Penelope Flohr1,Ines Figueiredo1,Diletta Bianchini2,Suzanne Carreira1,Ruth Riisnaes1,Susana Miranda1,Mateus Crespo1,Bora Gurel1,Maryou B. Lambros1,Claudia Bertan1,Matthew Clarke1,George Seed1,Ana Ferreira1,Ana Rita da Silva Pereira1,Emma Hall1,Johann de Bono2
1The Institute of Cancer Research,2The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

Dual ERK5 and AKT inhibition enhances the sensitivity of PTEN mutant triple negative breast cancer and glioblastoma cells to paclitaxel.

Year:

Session type:

Theme:

Akshita Bhatt1,Akshita Bhatt1,Thomas Wright1,Jordan Martin1,Katie Anna1,Seraina Schottland1,Jane Cavanaugh1
1Duquesne University

FOxTROT: an international randomised controlled trial in 1052 patients evaluating neoadjuvant chemotherapy for colon cancer

Year:

Session type:

Theme:

Dion Morton, on behalf of the FOxTROT investigators1
1University of Birmingham, Birmingham, UK

Repurposing of niclosamide (a putative STAT3 inhibitor) to potentiate chemotherapeutic drugs in treating colorectal cancer

Year:

Session type:

Theme:

Mia Mingxia Wu1,Christy Wing Sum Tong1,Wei Yan1,Kenneth Kin Wah To1
1The Chinese University of Hong Kong

Evaluation of older patients in early phase clinical trials

Year:

Session type:

Theme:

Jessica Lowe1,Rosie Lauste2,Tine Descamps3,Matthew Krebs1,Donna Graham1,Fiona Thistlethwaite1,Louise Carter1,Natalie Cook1
1The Christie NHS Foundation Trust, Manchester, UK,2University of Manchester, Manchester, UK,3Cancer Research UK, London, UK

Comparison of dosimetry from bowel bag and individual bowel loop contouring for patients receiving pelvic Stereotactic Ablative Radiotherapy (SABR) radiotherapy

Year:

Session type:

Theme:

Rhiannon Howells1,Eleanor Clarke1,Matthew Beasley2,Louise Murray3
1University of Leeds,2Leeds Cancer Centre,3Leeds Cancer Centre, University of Leeds

Investigating resistance mechanisms to glutaminase inhibition in renal cell carcinoma using a genome-wide CRISPR/Cas9 approach.

Year:

Session type:

Theme:

Aleksandra Raczka1,Aleksandra Raczka1,Paul Reynolds1
1School of Medicine, University of St Andrews

Making 3D possible: large scale organoid expansion using bioprocess design

Year:

Session type:

Theme:

Victoria Marsh Durban1,Mairian Thomas1,Kim Luetchford1,Trevor Dale1,Marianne Ellis1
1Cellesce Ltd

Investigating the anti-tumour effects of anti-PD-L1 immune checkpoint blockade combined with ionising radiation in the TrampC1 prostate cancer model.

Year:

Session type:

Theme:

Richard Bryant1,Yiannis Philippou1,Hanna Sjoberg1,Emma Murphy1,Said Alyacoubi1,Keaton Jones1,Alex Gordon-Weeks1,Gillies McKenna1,Uzi Gileadi1,Vincenzo Cerundolo1,Ian Mills1,Freddie Hamdy1,Ruth Muschel1
1University of Oxford

ABC-06 | A randomised phase III study of Active Symptom Control (ASC) with/without mFOLFOX after progression to Cisplatin-Gemcitabine chemotherapy for patients with advanced biliary tract cancers

Year:

Session type:

Theme:

Angela Lamarca1,Daniel H Palmer2,Harpreet Singh Wasan3,Paul J Ross4,Yuk Ting Ma5,Arvind Arora6,Stephen Falk7,Roopinder Gillmore8,Jonathan Wadsley9,Kinnari Patel10,Alan Anthoney11,Anthony Maraveyas12,Tim Iveson13,Justin S Waters14,Claire Blesing10,Safia Barber15,David Ryder15,John Ramage16,Linda Davies17,John A. Bridgewater18,Juan W Valle19
1The Christie NHS Foundation Trust, Manchester, UK,2University of Liverpool, Liverpool, UK,3Department of Cancer Medicine, Hammersmith Hospital, London, UK,4Guy's and St Thomas' NHS Foundation Trust, London, UK,5University of Birmingham, Birmingham, UK,6University Hospital of Nottingham NHS Trust, Nottingham, UK, University of Nottingham, Nottingham, UK,7Bristol Haematology and Oncology Centre, Bristol, UK,8Royal Free Hospital, London, UK,9Weston Park Hospital, Sheffield, UK,10Oxford University Hospitals, Oxford, UK,11Leeds Teaching Hospitals NHS Trust, Leeds, UK,12Castle Hill Hospital, Hull, UK,13University Hospital Southampton NHS Foundation Trust, Southampton, UK,14Kent Oncology Centre, Maidstone, UK,15Clinical Trials Unit, University of Manchester, Manchester, UK,16Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK,17Health Economics Department, University of Manchester, Manchester, UK,18University College London Cancer Institute, London, UK,19Institute of Cancer Sciences, University of Manchester, Manchester, UK, The Christie NHS Foundation Trust, Manchester, UK

Assessment of the Outcome of Treating Spinal Oligometastases with Stereotactic Ablative Body Radiotherapy

Year:

Session type:

Theme:

Helen Saxby1,Veni Ezhil2
1Charing Cross Hospital,2Royal Surrey County Hospital

Predicting risk of early relapse with circulating tumour DNA for advanced ER+ breast cancer patients in the PALOMA-3 trial

Year:

Session type:

Theme:

Ben O'Leary1,Rosalind Cutts1,Xin Huang2,Sarah Hrebien1,Yuan Liu2,Isaac Garcia-Murillas1,Fabrice Andre3,Sibylle Loibl4,Sherene Loi5,Massimo Cristofanilli6,Cynthia Huang Bartlett7,Nicholas Turner1
1The Institute of Cancer Research,2Pfizer,3Institut Gustave Roussy,4German Breast Group,5University of Melbourne,6Robert Lurie Cancer Centre,7Merck

A randomised phase III multicentre trial to evaluate the duration of anti-PD1 monoclonal antibody monotherapy in patients with metastatic melanoma (DANTE) – Stage 1 results

Year:

Session type:

Theme:

Sarah Danson1,Ruth Plummer2,Christian Ottensmeier3,Jane Hook4,Helen Marshall5,Gurdeep Sagoo5,David Meads5,Janine Bestall5,Galina Velikova5,Ferdia Gallagher6,Alexandra Smith5,Sue Bell5,Ellen Mason5,Eszter Katona5,Simon Rodwell7,Pippa Corrie8
1University of Sheffield, Sheffield, UK,2Newcastle University, Newcastle, UK,3University of Southampton, Southampton, UK,4Leeds Teaching Hospitals NHS Trust, Leeds, UK,5University of Leeds, Leeds, UK,6University of Cambridge, Cambridge, UK,7Melanoma Focus, Cambridge, UK,8Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Time on treatment and treatment patterns in patients with metastatic colorectal carcinoma: a retrospective chart review

Year:

Session type:

Theme:

Anna Ryan1,Daniel Sugrue2,Michael Hurst2,Pratik Thakkar3,Sidonie Hartridge-Lambert3,Hamzeh Kayhanian1,Jason Gordon2,Manuel Rodriguez-Justo1,Kai-Keen Shiu1,Dionysios Ntais3
1University College London Hospital,2Health Economics and Outcomes Research Ltd.,3Bristol-Myers Squibb

Peer review for target volume quality assurance at Guy’s Cancer Centre.

Year:

Session type:

Theme:

Pippa Lewis1,Renee Steel1,Teresa Guerrero Urbano1,Kathryn Innes1,Imran Hussain1,Barbara Fuller1
1Guy's and St Thomas' NHS Foundation Trust

Optimizing Chemotherapy for Frail and Elderly Patients with Advanced Gastroesophageal Cancer (aGOAC): the GO2 Phase III Trial.

Year:

Session type:

Theme:

Peter Hall1,Daniel Swinson2,Simon Lord3,Helen Marshall4,David Cairns4,Sharon Ruddock4,Emma Batman4,Galina Velikova4,Russell Petty5,Justin Waters6,Jonathan Wadsley7,Stephen Falk8,Catherine Handforth9,Rajarshi Roy10,Mano Joseph11,Konstantinos Kamposioras12,Jonathan Nicoll13,Tania Tillett14,Sebastian Cummins15,Simon Grumett16,Zuzana Stokes17,Tom Waddell18,Anirban Chatterjee19,Angel Garcia20,Christine Allmark21,Matthew Seymour22
1University of Edinburgh, Edinburgh, UK,2Leeds Teaching Hospitals NHS Trust, Leeds, UK,3University of Oxford, Oxford, UK,4University of Leeds, Leeds, UK,5University of Dundee, Dundee, UK,6Kent Oncology Centre, Maidstone, UK,7Western Park Hospital, Sheffield, UK,8Bristol Haematology and Oncology Centre, Bristol, UK,9University of Sheffield, Sheffield, UK,10Castle Hill Hospital, Hull, UK,11The Royal Wolverhampton NHS Trust, Wolverhampton, UK,12Mid Yorkshire Hospitals NHS Trust, Wakefield, UK,13North Cumbria University Hospitals NHS Trust, Carlisle, UK,14Royal United Hospital Bath NHS Trust, Bath, UK,15Royal Surrey County Hospital NHS Foundation Trust, Guilford, UK,16The Dudley Group NHS Foundation Trust, Dudley, UK,17United Lincolnshire Hospitals NHS Trust, Lincoln, UK,18The Christie NHS Foundation Trust, Manchester, UK,19The Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK,20The Shrewsbury and Telford Hospital NHS Trust,21NCRI Consumer Forum, London, UK,22University of Leeds

Repurposing loperamide to overcome gefitinib resistance by triggering apoptosis independent of autophagy induction in KRAS mutant NSCLC cells

Year:

Session type:

Theme:

Christy Wing Sum Tong1,Mia Mingxia Wu1,Wei Yan1,Kenneth Kin Wah To1
1The Chinese University of Hong Kong

PARP inhibition elicits tumour cell-intrinsic immune phenotypes in DNA repair deficient cancers.

Year:

Session type:

Theme:

Roman Chabanon1,Gareth Muirhead2,Dragomir Krastev2,Julien Adam1,Marlène Garrido1,Daphné Morel1,Nicolas Dorvault1,Rebecca Marlow3,Alan Ashworth4,Stephen Pettitt2,Syed Haider2,Andrew Tutt2,Aurélien Marabelle1,Jean-Charles Soria5,Christopher Lord2,Sophie Postel-Vinay1
1Gustave Roussy,2Institute of Cancer Research,3King's College London,4UCSF Helen Diller Family Comprehensive Cancer Centre,5AstraZeneca/MedImmune

PanCO: An Open-Label, Single-Arm Pilot Study of Phosphorus-32 Microparticles in Unresectable Locally Advanced Pancreatic Adenocarcinoma with FOLFIRINOX or Gemcitabine + Nab-Paclitaxel Chemotherapies

Year:

Session type:

Theme:

Paul Ross1,Natalie Phillips2,Zarni Win2,Christopher Wadsworth2,Thankamma Ajithkumar3,Luigi Aloj3,Edmund Godfrey3,Chinenye Iwuji4,Rakesh Ganatra4,Sudarshan Kadri4,Marion Harris5,Daniel Croagh5,Morteza Aghmesheh6,Adnan Nagrial7,Nam Nguyen8,Mehrdad Nikfarjam9,Alain Hendlisz10,Thomas Maher11,Anna Kraszewski11,Harpreet Wasan2
1Guy's & St Thomas' NHS Foundation Trust, London, UK,2Imperial College Healthcare NHS Trust, London, UK,3Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK,4University Hospitals of Leicester NHS Trust, Leicester, UK,5Monash Health, Melbourne, Australia,6Southern Medical Day Care Centre, Wollongong, Australia,7Westmead Hospital, Sydney, Australia,8Royal Adelaide Hospital, Adelaide, Australia,9Austin Health, Melbourne, Australia,10Institut Jules Bordet Université Libre de Bruxelles, Brussels, Belgium,11OncoSil Medical Ltd., Sydney, Australia

Large scale expansion of patient-derived breast cancer organoids to transform drug discovery screening assays

Year:

Session type:

Theme:

Mairian Thomas1,Andrew Hollins2,Trevor Dale2,Marianne Ellis1
1Cellesce Ltd,2Cardiff University

Pathological Response and Cardiotoxicity Following Neoadjuvant Dual Anti-HER2 Therapy: Early Experience at a New Cancer Centre.

Year:

Session type:

Theme:

Adam Henry1,Gerard Walls1,Goudarz Mazdai1,Linda McLaughlin1,Lucy Jellett1,Rhun Evans2
1NHS (Western Health and Social Care Trust),2NHS (Western and Social Care Trust)

BEACON: A Randomised, Phase 3 Study of Encorafenib and Cetuximab +/- Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E–Mutant Metastatic Colorectal Cancer Patients

Year:

Session type:

Theme:

Harpreet Wasan1,Tobias Arkenau2,Mike Braun3,Leslie Samuel4,Janet Graham5,Scott Kopetz6,Axel Grothey7,Eric Van Cutsem8,Rona Yaeger9,Takayuki Yoshino10,Jayesh Desai11,Fortunato Ciardello12,Ashwin Gollerkeri13,Kati Maharry13,Victor Sandor13,Janna Christy-Bittel13,Lisa Anderson13,Josep Tabernero14
1Hammersmith Hospital, London, UK,2Sarah Cannon Research Institute, London, UK,3Manchester Academic Health Science Centre and The Christie NHS Foundation Trust, Manchester, UK,4Aberdeen Royal Infirmary, Aberdeen, UK,5Beatson West Of Scotland Cancer Centre, Glasgow, UK,6UT MD Anderson Cancer Center, Houston, US,7West Cancer Center, University of Tennessee, Knoxville, US,8University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium,9Memorial Sloan-Kettering Cancer Center, New York, US,10National Cancer Center Hospital East, Kashiwa, Japan,11Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia,12University of Campania, Caserta, Italy,13Array BioPharma Inc, Boulder, US,14Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain

Anti-oestrogen medication use in breast cancer patients and subsequent risk of gastrointestinal cancers: a two country pooled analysis

Year:

Session type:

Theme:

Úna McMenamin1,Harlinde De Schutter2,Michael B Cook3,Stuart McIntosh4,Brian T Johnston5,Chris Cardwell1
1Queen's University Belfast, Belfast, UK,2Belgian Cancer Registry, Saint-Josse-ten-Noode, Belgium,3National Cancer Institute, Bethesda, US,4Belfast Health & Social Care Trust, Belfast, UK,5Belfast Health & Social Care Trust

Silvestrol sensitises breast cancer cells to radiation

Year:

Session type:

Theme:

Thomas Webb1
1East Kent Hospitals University NHS Foundation Trust, Kent, UK

Ad5NULL-A20 – a precision virotherapy that efficiently and selectively targets αvβ6 positive cancers following intravenous administration

Year:

Session type:

Theme:

Alan Parker1,James Davies1,Gareth Marlow1,Hanni Uusi-Kerttula1,Gillian Seaton1,Luke Piggott1,Richard Clarkson1,John Chester1
1Cardiff University, Cardiff, UK

COPELIA: A Randomised Phase II Trial of Cediranib in Combination with Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Cancer

Year:

Session type:

Theme:

Joanna Canham1,Gordon Jayson2,Robert Morgan2,Clare Freestone3,Angela Casbard4,Terri Kitson4,Alkesh Patel2,Chelsey Wheeler2,Rebecca Kristeleit5,Marcia Hall6,Louise Hanna7,Axel Walther8,Susana Banerjee9,Rene Roux10,Azmat Sadoyze11,Yvette Drew12,Andrew Clamp2
1WCTU, Cardiff University,2The Christie NHS Foundation Trust,3Centre For Trials Research,4Centre for Trials Research,5University College London,6Mount Vernon Hospital,7Velindre NHS Trust,8University Hospitals Bristol NHS Foundation Trust,9The Royal Marsden NHS Foundation Trust,10Oxford University Hospitals NHS Foundation Trust,11Greater Glasgow Health Board,12The Newcastle upon Tyne Hospitals NHS Foundation Trust

Adaptive Radiotherapy for Cancer of the Head and Neck guided by Intra-treatment ¹⁸F-FDG-PET and MRI scanning – Proposal for a Phase 1 feasibility study

Year:

Session type:

Theme:

Delali Adjogatse1,Andriana Michaelidou2,Yae-Eun Suh3,Lucy Pike2,Christopher Thomas4,Sally Barrington2,Lei Mary3,Teresa Guerrero Urbano3
1Dept of Oncology, Guy's and St Thomas NHS Foundation Trust, London, UK,2King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London,3Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London,4King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London AND Department of Medical Physics, Guy's and St Thomas' NHS Foundation Trust, London

Assessment of the effect of oncolytic virotherapy in combination with cavitational ultrasound in the treatment of colorectal liver metastases using a precision cut tumour slice model

Year:

Session type:

Theme:

Marcos Kostalas1,Joshua Owen2,Claudia Hill2,Christopher Smith3,Nicola Annels3,Robert Carlisle2,Hardev Pandha3
1Royal Surrey County Hospital, Guildford, UK,2University of Oxford, Oxford, UK,3University of Surrey, Guildford, UK

Real world treatment sequencing patterns in secondary breast cancer (SBC): Pathway visualisation using national datasets.

Year:

Session type:

Theme:

Ashley Horne1,Maria McMenemy2,Holly Ennis3,Lauren Murdoch3,Grace Ding1,Olga Oikonomidou1,Caroline Michie1,Larry Haywood1,David Cameron1,Christina Lilley1,Peter Hall4,Alison Stillie1,Aisling Hennessy1,Frances Yuille1
1Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK,2Lothian Analytical Services, NHS Lothian, Edinburgh, UK,3Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK,4Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK

Identification and validation of natural anti-drug resistant and anticancer stem cell agents in TNBC stem cells

Year:

Session type:

Theme:

Prem Kushwaha1,Shashank Kumar1
1Central University of Punjab, Punjab, India

Cell culture under perfusion conditions reduces cellular metabolic stress and mimics the in vivo physiological environment in pancreatic cancer

Year:

Session type:

Theme:

Daniel Hughes1,Frances Willenbrock2,Zahir Soonawalla3,Srikanth Reddy3,Michael Silva3,Somnath Mukherjee3,Eric O'Neill2
1University of Oxford, Oxford, UK,2Department of Oncology, University of Oxford, Oxford, UK,3Oxford University Hospitals, Oxford, UK

A systematic review of outcome reporting in early phase studies of colorectal cancer surgical innovation

Year:

Session type:

Theme:

Christin Hoffmann1,Kerry NL Avery1,Shelley Potter2,Nicholas Wilson1,Rhiannon Macefield1,Natalie Blencowe3,Sean Cousins1,Jane M Blazeby1,Angus GK McNair4
1Centre for Surgical Research, Bristol Medical School: Population Health Sciences, University of Bristol,21 Centre for Surgical Research, Bristol Medical School: Population Health Sciences, University of Bristol; 2 Bristol Breast Care Centre, North Bristol NHS Trust, Bristol, UK,31 Centre for Surgical Research, Bristol Medical School: Population Health Sciences, University of Bristol; 2 Division of Surgery Head and Neck, University Hospitals Bristol NHS Foundation Trust, Bristol, UK,41 Centre for Surgical Research, Bristol Medical School: Population Health Sciences, University of Bristol; 2 Department of Gastrointestinal Surgery, North Bristol NHS Trust, Bristol, UK

Impact of lung and cardiac dose on the survival of oesophageal cancer patients following single modality radiotherapy

Year:

Session type:

Theme:

Matthew Hatton1,Bilal Tahir2,Helen Joyce3,Lynne Dixon3,Joseph Bradshaw4,Selina Hardy4,Stephen Tozer-Loft4,Jon Wadsley5
1Weston Park Hospital,2Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, UK,3Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK,4Department of Radiotherapy Physics, Weston Park Hospital, Sheffield, UK,5Academic Unit of Clinical Oncology, University of Sheffield, Sheffield

Should major surgery be offered to elderly patients with early-stage lung cancer? An emulated trial using observational data in England

Year:

Session type:

Theme:

Camille Maringe1,Clémence Leyrat1,Sara Benitez Majano1,Aimilia Exarchakou1,Matthew Smith1,Bernard Rachet1,Aurélien Belot1
1London School of Hygienen and Tropical Medicine, London, UK

Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal cancer (aGOAC): The uncertain randomization of the GO2 phase III trial

Year:

Session type:

Theme:

Daniel Swinson1,Peter Hall2,Mohan Hingorani3,Zuzani Stokes4,Jo Dent5,Kamalnayan Guptal6,Anirban Chatterjee7,Konstantinos Kamposioras8,Simon Aird Grumett9,Mohammad Khan10,Helen Marshall11,Ruddock Sharon11,Cairns David11,Christine Allmark12,Eszter Katona11,Helen C Howard11,Galina Velikova13,Simon Lord14,Matthew T Seymour15
1St James's University Hospital, Leeds, UK,2University of Edinburgh, Edinburgh.,3St James's University Hospital, Leeds.,4Lincolnshire Hospitals, Lincoln,5Calderdale and Huddersfield Royal Infirmary,6Worcester, United Kingdom,7Shrewsbury & Telford Hospitals, Shrewsbury,8Christie Hospital, Manchester,9Royal Wolverhampton Hospitals, Wolverhampton,10Scarborough Hospital, Scarborough,11CTRU, University of Leeds, Leeds,12NCRI Consumer Forum, London,13University of Leeds, Leeds,14University of Oxford, Oxford,15National Institute for Health Research Clinical Research Network, Leeds, United Kingdom

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in patients with metastatic colorectal cancer

Year:

Session type:

Theme:

Jamal Zekri1,Ehab Mosaad2,Refaei Belal Ibrahim3,Kamel Mohamed Kamal4,Adnan Hussain5,Mohammed Abbas Baghdadi6
1College of Medicine, Al-Faisal University, King Faisal Specialist Hospital (Jeddah),2Medical oncology department, National Cancer Institute, Cairo University,3Department of clinical oncology and nuclear medicine. Faculty of medicine Al Azhar University,4Cairo University,5King Faisal Specialist Hospital and Research Center- Jeddah,6Research Centre, King Faisal Specialist Hospital & Research Centre, Jeddah

Does recruitment to cancer clinical trials at the Leicester Royal Infirmary reflect the ethnic diversity of those receiving systemic anticancer therapy?

Year:

Session type:

Theme:

Adrian Nicholson1,Mohammed Karolia1,Emily de Groot2,Sarah Nicholson1,Devinder Dhillon1,Lynne Howells3,Harriet Walter3,Anne Thomas3
1University Hospitals Leicester, Leicester, UK,2University of Leicester Medical School, Leicester, UK,3Leicester Cancer Research Centre, Leicester, UK

Predicting platinum chemotherapy sensitivity in advanced oesophageal cancer using a DNA Damage Immune Response (DDIR) assay

Year:

Session type:

Theme:

Mark Baxter1,Shaun Walsh2,Russell Petty1
1University of Dundee,2NHS Tayside

Assessment and monitoring of cardiotoxicity in Breast Cancer patients treated with  HER2-directed Agents (Trastuzumab, Pertuzumab, and Ado-trastuzumab emtansine (T-DM1)

Year:

Session type:

Theme:

Sudha Karanam1,Mariam Jafri1,Daniel Rea1,Nyein Su Tun1
1University Hospital Birmingham NHS Trust

Making Outcome-Based Payment for Cancer Medicines a Reality in the NHS

Year:

Session type:

Theme:

Amanda Cole1,Patricia Cubi-Molla1,Jack Pollard2,Duncan Sim3,Richard Sullivan4,Jon Sussex2,Paula Lorgelly4
1Office of Health Economics, London, UK,2RAND Europe, Cambridge, UK,3Cancer Research UK, London, UK,4King's College London, London, UK

Addressing the variation in adjuvant chemotherapy treatment for colorectal cancer (CRC): can a regional intervention promote national change?

Year:

Session type:

Theme:

Daniel Swinson1,John C. Taylor2,Jenny F. Seligmann3,Rebecca Birch4,Alice Dewdney5,Hannah Rossington4,Victoria A. Brown6,Jo Dent7,Philip Quirke8,Eva J. A. Morris4
1St James's University Hospital, Leeds, UK,2Leeds Institute of Data Analytics, University of Leeds, Leeds, UK,3St James's University Hospital, Leeds, UK, Leeds Teaching Hospitals Trust, Leeds, Leeds, UK,4Cancer Epidemiology Group, Leeds, UK, Section of Epidemiology and Biostatistics, Leeds, UK, Leeds Institute of Cancer & Pathology, Leeds, UK, Leeds Institute for Data Analytics, University of Leeds, Leeds, UK,5Department of Radiotherapy, Weston Park Hospital, Sheffield, UK, Sheffield Teaching Hospitals, Sheffield, UK,6Queen’s Centre for Oncology and Haematology, Hull, UK, Hull University Hospitals NHS Trust, Hull, UK,7Department of Oncology, Huddersfield Royal Infirmary, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, UK,8Section of Pathology and Tumour Biology, Leeds, UK, Leeds Institute of Cancer & Pathology, Leeds, UK, University of Leeds, Leeds, UK

Safety and efficacy of 12 mg/d lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma (uHCC) and bodyweight >80 kg in REFLECT

Year:

Session type:

Theme:

Arndt Vogel1,Masatoshi Kudo2,Ann-Lii Cheng3,Max W. Sung4,Richard S. Finn5,Albert Y. Lin6,Ghassan K. Abou-Alfa7,Angel Alsina8,Valeriy Breder9,Niall Tebbutt10,Pia Osterlund11,C. J. Yen12,Min Ren13,Soamnauth Misir13,Corina E. Dutcus13,Daniel Palmer14,Philippe Merle15,Matthias Pinter16,TR Jeffry Evans17
1Hannover Medical School,2Kindai University School of Medicine,3National Taiwan University Hospital,4Tisch Cancer Institute at Mount Sinai,5Geffen School of Medicine, UCLA Medical Center,6VA Palo Alto Health Care System,7Memorial Sloan Kettering Cancer Center,8Tampa General Hospital,9N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation,10Olivia Newton-John Cancer Centre,11Tampere University and Central Hospital,12National Cheng Kung University Hospital,13Eisai Inc.,14University of Liverpool, Liverpool,15CHU de Lyon -Hospital La Croix-Rousse,16Medical University of Vienna,17University of Glasgow

Xentuzumab (BI 836845), an IGF-neutralizing antibody, combined with exemestane and everolimus in hormone receptor-positive (HR+) locally advanced/metastatic breast cancer: Randomized Phase 2 results

Year:

Session type:

Theme:

John Crown1,Marie-Paule Sablin2,Javier Cortés3,Jonas Bergh4,Seock-Ah Im5,Yen-Shen Lu6,Noelia Martínez7,Patrick Neven8,Keun Seok Lee9,Serafín Morales10,J. Alejandro Pérez-Fidalgo11,Douglas Adamson12,Anthony Goncalves13,Aleix Prat14,Guy Jerusalem15,Laura Schlieker16,Rosa-Maria Espadero17,Thomas Bogenrieder18,Dennis Chin-Lun Huang19,Peter Schmid20
1St Vincent University Hospital, Dublin, Ireland,2Institut Curie, Paris, France,3IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain,4Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden,5Seoul National University Hospital, Seoul, South Korea,6National Taiwan University Hospital, Taipei, Taiwan,7IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain,8UZ Leuven, Campus Gasthuisberg, Lueven, Belgium,9National Cancer Center, Goyang, South Korea,10Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain,11Hospital Clinico Universitario Valencia, Spain, Biomedical Research Institute INCLIVA, Valencia, Spain, el Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain,12Tayside Cancer Centre, Ninewells Hospital, Dundee, UK,13Institut Paoli Calmettes, Marseille, France,14Hospital Clínic de Barcelona Servicio de Oncología Médica, Barcelona, Spain,15Centre Hospitalier Universitaire de Liège, Belgium, Liège University, Liège, Belgium,16External statistician on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Bracknell, UK, Staburo GmbH & Co. KG. Staburo GmbH, Munich, Germany,17Boehringer Ingelheim España S.A, Barcelona, Spain,18Boehringer Ingelheim RCV, Vienna, Austria,19Boehringer Ingelheim Taiwan Limited, Taipei, Taiwan,20Centre for Experimental Cancer Medicine, Barts Cancer Institute, London, UK, Queen Mary University of London, London, UK